These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 7319130)

  • 1. Post-marketing surveillance: drug epidemiology.
    Borden EK
    J Int Med Res; 1981; 9(6):401-7. PubMed ID: 7319130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assuring the safety and efficacy of therapies.
    Stolley PD
    Int J Health Serv; 1974; 4(1):131-45. PubMed ID: 4597990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can postmarketing surveillance help to effect optimal drug therapy?
    Strom BL; Melmon KL
    JAMA; 1979 Nov; 242(22):2420-2. PubMed ID: 385922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal therapy for the geriatric patient: the challenge to clinical pharmacology.
    Crapo LM; Melmon KL
    J Chronic Dis; 1983; 36(1):39-52. PubMed ID: 6848547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-marketing surveillance.
    Culliton BJ; Waterfall WK
    Br Med J; 1980 May; 280(6224):1175-6. PubMed ID: 7388453
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug utilization studies within the VIDEOFAR project.
    Maggini M; Menniti Ippolito F; Spila Alegiani S; Traversa G; Fortini M
    Ann Ist Super Sanita; 1991; 27(2):201-6. PubMed ID: 1755571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of the Pharmaceuticals and Medical Devices Agency and healthcare professionals in post-marketing safety.
    Mori K; Watanabe M; Horiuchi N; Tamura A; Kutsumi H
    Clin J Gastroenterol; 2014 Apr; 7(2):103-7. PubMed ID: 26183623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ethics of post-marketing surveillance of therapeutic agents.
    Beran RG
    Med Law; 2001; 20(4):587-94. PubMed ID: 11817390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methods of monitoring adverse reactions to drugs.
    Venulet J
    Prog Drug Res; 1977; 21():231-92. PubMed ID: 339270
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of drug use data in public health research.
    Vegni FE; Wilkinson P
    Ann Ig; 2004; 16(3):487-95. PubMed ID: 15368940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trials in post-marketing surveillance of drugs.
    Bell RL; Smith EO
    Control Clin Trials; 1982 Mar; 3(1):61-8. PubMed ID: 7067472
    [No Abstract]   [Full Text] [Related]  

  • 12. Filtering big data from social media--Building an early warning system for adverse drug reactions.
    Yang M; Kiang M; Shang W
    J Biomed Inform; 2015 Apr; 54():230-40. PubMed ID: 25688695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA drug labeling for pregnancy and lactation drug safety monitoring systems.
    Greene MF
    Semin Perinatol; 2015 Nov; 39(7):520-3. PubMed ID: 26428020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse drug reactions: the need for detection and control.
    Cluff LE
    Am J Epidemiol; 1971 Nov; 94(5):405-8. PubMed ID: 5120538
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluating drugs and determining the drug needs of developed and developing countries.
    Stolley PD
    J Community Health; 1976; 2(2):113-20. PubMed ID: 1016340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specialist Cohort Event Monitoring studies: a new study method for risk management in pharmacovigilance.
    Layton D; Shakir SA
    Drug Saf; 2015 Feb; 38(2):153-63. PubMed ID: 25564333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methodological issues in using drugs data in epidemiology.
    Vegni FE; Wilkinson P
    Ann Ig; 2004; 16(3):479-85. PubMed ID: 15368939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pediatric post-marketing safety systems in North America: assessment of the current status.
    McMahon AW; Wharton GT; Bonnel R; DeCelle M; Swank K; Testoni D; Cope JU; Smith PB; Wu E; Murphy MD
    Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):785-92. PubMed ID: 26098297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pre-marketing ALT signal predicts post-marketing liver safety.
    Moylan CA; Suzuki A; Papay JI; Yuen NA; Ames M; Hunt CM
    Regul Toxicol Pharmacol; 2012 Aug; 63(3):433-9. PubMed ID: 22668747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A research roadmap for complementary and alternative medicine - what we need to know by 2020.
    Fischer F; Lewith G; Witt CM; Linde K; von Ammon K; Cardini F; Falkenberg T; Fønnebø V; Johannessen H; Reiter B; Uehleke B; Weidenhammer W; Brinkhaus B
    Forsch Komplementmed; 2014; 21(2):e1-16. PubMed ID: 24851850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.